Overview

Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

Status:
Active, not recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia. Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment. Group 2: Initial treatment. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
Phase:
Phase 3
Details
Lead Sponsor:
The University of Queensland
Collaborators:
Griffith University
Princess Alexandra Hospital, Brisbane, Australia
Queensland Children's Hospital, Australia
Queensland Children's Hospital, Brisbane, Australia
Telethon Kids Institute
The Prince Charles Hospital
Treatments:
Broncho-Vaxom